Clinical Trial Update: Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind safety and efficacy study of lisdexamfetamine dimesylate in children and adolescents with ADHD has completed; results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• LISDEXAMFETAMINE DIMESYLATE (Lisdexamfetamine dimesylate)

Snippet

Sponsor: Shire | Conditions: ADHD | Phase 3 | Status: COMPLETED | Results posted: 2012-03-22